RenovoRx (RNXT) Common Equity (2020 - 2026)

RenovoRx has disclosed Common Equity across 7 years of filings, most recently posting $9.0 million for Q2 2026.

• In Q2 2026, Common Equity fell 15.62% year-over-year to $9.0 million; the TTM figure through Jun 2026 stood at $9.0 million (down 15.62% YoY), while the FY2025 annual figure was $5.4 million, up 21.08% from the prior year.
• Common Equity came in at $9.0 million for Q2 2026 at RenovoRx, down from $11.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $13.2 million in Q1 2025 to a low of $6000.0 in Q3 2023.
• Average Common Equity over 5 years is $6.9 million, with a median of $7.6 million recorded in 2024.
• Year-over-year, Common Equity tumbled 99.93% in 2023 and soared 117750.0% in 2024.
• Over 5 years, Common Equity stood at $6.2 million in 2022, then plunged by 51.32% to $3.0 million in 2023, then jumped by 49.27% to $4.5 million in 2024, then gained by 21.08% to $5.4 million in 2025, then soared by 65.6% to $9.0 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $9.0 million in Q2 2026, $11.3 million in Q1 2026, and $5.4 million in Q4 2025.